论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Sun T, Zou K, Yuan Z, Yang C, Lin X, Xiong B
Received 10 March 2017
Accepted for publication 9 June 2017
Published 4 August 2017 Volume 2017:10 Pages 3907—3916
DOI https://doi.org/10.2147/OTT.S136530
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr Faris Farassati
Background: Many
studies have assessed the clinical use of circulating tumor cells (CTCs) in
head and neck cancer, but the clinicopathological and prognostic significance
of CTCs is still unclear.
Materials and
methods: Two authors systematically searched the
studies independently with keywords in PubMed, MEDLINE, EMBASE, Science
Citation Index Expanded and Cochrane Library (from inception to February 2017).
The estimated hazard ratio (HR), risk ratio (RR) and their 95% confidence
intervals (95% CIs) were set as effect measures. All analyses were performed by
STATA 12.0.
Results: A total of 17 studies were included in this meta-analysis.
Positive CTCs were significantly associated with poor overall survival (HR
=2.80, 95% CI: 1.34–5.86), disease-free survival (HR =3.86, 95% CI: 2.03–7.36)
and progression-free survival (HR =3.31, 95% CI: 1.71–6.42). CTC-positive
patients tend to have higher recurrence (RR =2.13, 95% CI: 1.26–3.59) and
regional lymph node metastasis (RR =1.18, 95% CI: 1.02–1.36) rate and a more
advanced tumor stage (RR =1.16, 95% CI: 1.03–1.32).
Conclusion: Our meta-analysis has confirmed the significant prognostic value of CTCs
in head and neck cancer patients. The presence of CTCs could be used as a
monitoring tool for tumor status of head and neck cancer, especially for the
early detection of the tumor recurrence and progression, advanced disease and
the node metastasis.
Keywords: head and neck cancer, circulating tumor cells, prognostic,
clinicopathological characteristics, meta-analysis